137 related articles for article (PubMed ID: 11328664)
41. [Pharmacological study of ebastine, a novel histamine H1-receptor antagonist].
Yakuo I; Ishii K; Seto Y; Imano K; Takeyama K; Nakamura H; Karasawa T
Nihon Yakurigaku Zasshi; 1994 Mar; 103(3):121-35. PubMed ID: 7511558
[TBL] [Abstract][Full Text] [Related]
42. The effect of food on the bioavailability of ebastine.
Pentikis HS; Huang MY; Dorr MB; Heald DL
Am J Ther; 1997; 4(2-3):80-4. PubMed ID: 10423596
[TBL] [Abstract][Full Text] [Related]
43. Microbial oxidation of ebastine.
Schwartz H; Liebig-Weber A; Hochstätter H; Böttcher H
Appl Microbiol Biotechnol; 1996 Feb; 44(6):731-5. PubMed ID: 8867630
[TBL] [Abstract][Full Text] [Related]
44. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects.
Mattila MJ; Kuitunen T; Plétan Y
Eur J Clin Pharmacol; 1992; 43(2):179-84. PubMed ID: 1358620
[TBL] [Abstract][Full Text] [Related]
45. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
Fujii S; Setoguchi C; Kawazu K; Hosoya K
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
[TBL] [Abstract][Full Text] [Related]
46. Method development and validation for simultaneous determination of ebastine and its active metabolite carebastine in human plasma by liquid chromatography-tandem mass spectrometry and its application to a clinical pharmacokinetic study in healthy Chinese volunteers.
Phiri M; Li D; Li T; Ji S; Ling T; Li X; Gao H; Ding L; Shu C
Biomed Chromatogr; 2020 Oct; 34(10):e4904. PubMed ID: 32449558
[TBL] [Abstract][Full Text] [Related]
47. Carrier-mediated transport of H1-antagonist at the blood-brain barrier: a common transport system of H1-antagonists and lipophilic basic drugs.
Yamazaki M; Terasaki T; Yoshioka K; Nagata O; Kato H; Ito Y; Tsuji A
Pharm Res; 1994 Nov; 11(11):1516-8. PubMed ID: 7870663
[TBL] [Abstract][Full Text] [Related]
48. Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models.
Jähne EA; Eigenmann DE; Culot M; Cecchelli R; Walter FR; Deli MA; Tremmel R; Fricker G; Smiesko M; Hamburger M; Oufir M
J Pharm Biomed Anal; 2014 Sep; 98():235-46. PubMed ID: 24949819
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs.
Puigdemont A; Queralt M; Jansat JM; Martinez-Tobed A
J Pharm Pharmacol; 1994 Jul; 46(7):596-9. PubMed ID: 7996390
[TBL] [Abstract][Full Text] [Related]
50. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies.
Kido Y; Tamai I; Okamoto M; Suzuki F; Tsuji A
Pharm Res; 2000 Jan; 17(1):55-62. PubMed ID: 10714609
[TBL] [Abstract][Full Text] [Related]
51. Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT.
Régina A; Romero IA; Greenwood J; Adamson P; Bourre JM; Couraud PO; Roux F
J Neurochem; 1999 Nov; 73(5):1954-63. PubMed ID: 10537053
[TBL] [Abstract][Full Text] [Related]
52. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis.
Frank H; Gillen M; Rohatagi SS; Lim J; George G;
J Clin Pharmacol; 2002 Oct; 42(10):1097-104. PubMed ID: 12362923
[TBL] [Abstract][Full Text] [Related]
53. Simultaneous determination of the histamine H1-receptor antagonist ebastine and its two metabolites, carebastine and hydroxyebastine, in human plasma using high-performance liquid chromatography.
Matsuda M; Mizuki Y; Terauchi Y
J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(1):173-9. PubMed ID: 11419742
[TBL] [Abstract][Full Text] [Related]
54. Preclinical comparison of ebastine and other second generation H1-antihistamines.
Yakuo I; Yabuuchi M; Ito T
Pharmacol Toxicol; 2001 Oct; 89(4):171-6. PubMed ID: 11881966
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats.
Ohtani H; Sato H; Iga T; Kotaki H; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):101-6. PubMed ID: 10206325
[TBL] [Abstract][Full Text] [Related]
56. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study.
Gervasini G; Vizcaino S; Carrillo JA; Caballero MJ; Benitez J
Br J Clin Pharmacol; 2006 Aug; 62(2):177-86. PubMed ID: 16842392
[TBL] [Abstract][Full Text] [Related]
57. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo.
Sadiq MW; Borgs A; Okura T; Shimomura K; Kato S; Deguchi Y; Jansson B; Björkman S; Terasaki T; Hammarlund-Udenaes M
J Pharm Sci; 2011 Sep; 100(9):3912-23. PubMed ID: 21472729
[TBL] [Abstract][Full Text] [Related]
58. Cardiac effects of ebastine and other antihistamines in humans.
Moss AJ; Morganroth J
Drug Saf; 1999; 21 Suppl 1():69-80; discussion 81-7. PubMed ID: 10597870
[TBL] [Abstract][Full Text] [Related]
59. The non-cardiac systemic side-effects of antihistamines: ebastine.
Roberts DJ; Gispert J
Clin Exp Allergy; 1999 Jul; 29 Suppl 3():151-5. PubMed ID: 10444230
[TBL] [Abstract][Full Text] [Related]
60. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
Tamai I; Yamashita J; Kido Y; Ohnari A; Sai Y; Shima Y; Naruhashi K; Koizumi S; Tsuji A
J Pharmacol Exp Ther; 2000 Oct; 295(1):146-52. PubMed ID: 10991972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
